POZ parties are an emerging risk for HIV-infected men who have unprotected sex with men. In a recent report, researchers in the United States conducted a study to "develop a preliminary epidemiological description of a men who have sex with men (MSM) 'POZ Party', an emerging sex environment for HIV+MSM. As part of a pilot study in New York City in 2003, data were collected using a brief, behavioral intercept survey at entry to POZ Party events.
HIV-1 buffers the effects of potentially detrimental variations in essential viral and cellular functions. According to recent research published in the Biophysical Journal, "The persistence of human immunodeficiency virus type-1 (HIV-1) has long been attributed to its high mutation rate and the capacity of its resulting heterogeneous virus populations to evade host immune responses and antiviral drugs.
HIV-1 Tat selectively enhances CXCR4 and inhibits CCR5 expression in megakaryocytes. According to a study from the United States, "The hematopoietic compartments act as long-term reservoirs for human immunodeficiency virus type-1 (HIV-1). Although hematopoietic progenitor cells (HPCs) are rarely infectable, HPCs committed to the megakaryocytic lineage can be infected and support a productive infection by both the X4 and R5 strains of HIV-1.
HIV Tat alters circadian rhythms through the light entrainment pathway. "Patients infected with the human immunodeficiency virus (HIV), and other mammals infected with related lentiviruses, exhibit fatigue, altered sleep patterns, and abnormal circadian rhythms. A circadian clock in the hypothalamic suprachiasmatic nucleus (SCN) temporally regulates these functions in mammals," investigators in the United States report.
HLA class II alleles are associated with HIV-1 pathogenesis in Botswana. "Southern Africa is facing an unprecedented public health crisis due to the high prevalence of human immunodeficiency virus type 1 (HIV-1). Vaccine development and testing efforts, mainly based on elicitation of HIV-specific T cells, are under way.
Cumulative HAART exposure increases the risk of side effect-related morbidity in HIV-infected children. "Although highly active antiretroviral therapy (HAART) has positively altered the mortality rates in HIV-infected children, these drugs have the potential to cause significant morbidity.
Nonbrothel based female sex workers are at higher risk of HIV infection than brothel-based workers in India. According to recent research from India, "Heterosexual contact is the most common mode of HIV transmission in India that is largely linked to sex work. We assessed the nonuse of condoms in sex work and with regular sex partners by female sex workers (FSWs), and identified its associations that could assist in planning HIV prevention programs.
Indevus Pharmaceuticals, Inc., (IDEV) has initiated a large, international phase III clinical trial of PRO 2000, the company's topical, vaginal microbicide in development for the prevention of sexually transmitted infections, including HIV, herpes, chlamydia and gonorrhea. The trial is being sponsored by the Medical Research Council of the United Kingdom (MRC) and conducted by the U.K. government-funded Microbicides Development Programme (MDP).
HIV-1 variants from single plasma samples have various neutralization sensitivities. According to recent research from France, "Individuals infected with human immunodeficiency virus type 1 (HIV-1) harbor a mixture of viral variants with different sequences and in some instances with different phenotypic properties.
The CCR5 ORF Δ32/wt-CCR5 -2459 A/G genotype combination is advantageous in resisting sexual HIV-1 transmission. "Exposed seronegative individuals (ES) with persistent high-risk sexual behavior may be less susceptible to human immunodeficiency virus type 1 (HIV-1) infection because they carry the chemokine receptor (CR) gene alleles CCR5 open reading frame (ORF) Δ32, CCR5 promoter -2459G, or CCR2 ORF 641 (CCR2-641), all of which have been found to diminish HIV-1 infectivity and/or disease progression.
CCR5+CD4+ cells are highly activated during primary HIV-1 infection. According to a study from Australia, "We investigated whether HIV-1 antigen-specific CD4+ T cells expressed the viral coreceptor CCR5 during primary HIV-1 infection (PHI)."
The plant extract scutellarin inhibits HIV-1 RT, particle attachment and cell fusion. According to recent research from People's Republic of China, "Scutellarin was purified from the plant Erigeron breuiscapus (Vant.) Hand-Mazz.
Genetically engineered live bacteria block HIV fusion and entry. "Most HIV transmission occurs on the mucosal surfaces of the gastrointestinal and cervicovaginal tracts, both of which are normally coated by a biofilm of nonpathogenic commensal bacteria. We propose to genetically engineer such naturally occurring bacteria to protect against HIV infection by secreting antiviral peptides," scientists in the United States report.
De novo drug-resistance mutations are selected during the first HIV treatment interruption cycle. According to a recently published report from Spain, "Structured treatment interruption (STI) may allow viral replication in the presence of decreased plasma drug levels, with risk of selection of resistance mutations.
Cotrimoxazole prophylaxis prevents complications prior to the initiation of HAART. According to recent research from France, "In 2000, WHO/UNAIDS recommended cotrimoxazole prophylaxis for persons at early stages of HIV infection (WHO stage >2) in sub-Saharan Africa." The cost-effectiveness of alternative strategies for initiation of cotrimoxazole in Cote d'lvoire" was assessed with an "HIV simulation model using clinical and cost data from a randomized trial of cotrimoxazole in HIV-infected adults."
GB virus C inhibition of HIV is mediated by CD4 and CD8 T-cell-derived soluble factors. According to a study from Germany, "A number of studies concerning the pathogenesis of GB virus C (GBV-C) in HIV-infected people suggest a beneficial effect and improved survival for dually infected individuals. However there has remained controversy regarding the clinical relevance of these findings, as some studies have not confirmed these observations."
A cervicovaginal organ culture system was developed to determine HIV transmission events after exposure. "We have developed human cervicovaginal organ culture systems to examine the initiating events in HIV transmission after exposure to various sources of HIV infectivity, including semen. Newly infected cells were detected in the cervical submucosa 3-4 days after exposure to a primary HIV isolate.
Low-level antigen exposure is sufficient for sustained HIV-specific immunity. According to a study from the Netherlands, "Long-term nonprogressive HIV infection, characterized by low but detectable viral load and stable CD4 counts in the absence of antiviral therapy, is observed in about 5% of HIV-infected patients.
CD4 percent values in HIV-infected children are unreliable due to measurement error. "Our objective was to develop data-based algorithms for definition of immunologic response to AIDS therapies in pediatric patients, taking account of T-cell subset measurement errors. The study design involved cross-protocol analysis of 2,148 enrollees in 6 completed Pediatric AIDS Clinical Trials Group trials," researchers in the United States report.
CD4+CD25+ regulatory T cells are crucial in HIV infection. According to a recent review from the United States, "The immune system faces the difficult task of discerning between foreign, potentially pathogen-derived antigens and self-antigens.
HIV-1 group M isolates are 100-fold-more fit than group 0 or HIV-2 strains. According to recent research from the United States, "The main (M) group of human immunodeficiency virus type 1 (HIV-1) is responsible for the global AIDS epidemic while HIV-1 group O (outlier) and HIV type 2 are endemic only in west and central Africa.
A microchip CD4 counting method monitors HIV in resource-poor settings. "More than 35 million people in developing countries are living with HIV infection. An enormous global effort is now underway to bring antiretroviral treatment to at least 3 million of those infected," scientists in the United States report.
Aerobics increases high-density lipoprotein cholesterol in HAART-associated lipodystrophy. According to recent research published in the journal HIV Medicine, "Lipodystrophy in HIV-infected (LDHIV) patients receiving protease inhibitors (PIs) is associated with dyslipidemia. Whether lifestyle factors play a role in dyslipidemia in LDHIV subjects on PIs is not well characterized."
Total lymphocyte counts and hemoglobin levels are used to monitor HIV progression. According to a study from the United States, "Prognostic markers for HIV monitoring are needed for resource-limited regions. Prior research has demonstrated rapid declines in total lymphocyte count (TLC) and hemoglobin levels before AIDS, but the prognostic accuracy of these declines has not been examined prospectively.
Viral suppression is similar in patients retreated with HAART and in patients on continuous HAART. In a recent report published in the Journal of Acquired Immune Deficiency Syndromes, researchers in Thailand conducted a study "to assess the safety of 2 intermittent treatment strategies compared with continuous therapy for patients with virologic suppression on highly active antiretroviral therapy (HAART) at baseline."
There is limited viral evolution within persistently targeted CD8 T cell epitopes in chronic HIV-1 infection. According to a study from the United States, "Studies in acute human immunodeficiency virus type 1 (HIV-1) infection indicate viral evolution under CD8 T-cell immune selection pressure, but the effects of ongoing immune pressure on epitope evolution during chronic infection are not well described.
HIV-1 Vpr impairs dendritic cell maturation and T cell activation. According to recent research from the United States, "Antigen presentation and T-cell activation are dynamic processes involving signaling molecules present in both APCs and T cells. Effective APC function and T-cell activation can be compromised by viral immune evasion strategies, including those of human immunodeficiency virus type 1 (HIV-1)."
C-reactive protein is useful for monitoring intercurrent infection in HIV-1-infected patients. "The acute-phase protein C-reactive protein (CRP) is a sensitive marker of inflammation and tissue damage. We measured CRP in 109 HIV-1 antibody-positive patients admitted to hospital for investigation," researchers in United Kingdom report.
HIV postexposure prophylaxis is not routinely offered following sexual assault. "Although rare, HIV transmission is one of the most feared consequences of sexual assault. While availability of medications to prevent HIV transmission (HIV nonoccupational postexposure prophylaxis [HIV nPEP]) is increasing, little is known about emergency department (ED) prescribing practices and patient adherence to treatment recommendations.
CD91 expression is increased on monocytes of exposed yet HIV-1-seronegative subjects. "The significantly higher surface expression of the surface heat-shock protein receptor CD91 on monocytes of human immunodeficiency virus type-1 (HIV-1)-infected, long-term nonprogressors suggests that HIV-1 antigen uptake and cross-presentation mediated by CD91 may contribute to host anti-HIV-1 defenses and play a role in protection against HIV-1 infection.
HIV-1 RNA from dried-blood spot samples correlates with plasma viral load. According to a recently published report from Mexico, "To measure HIV-1 RNA concentration requires venous extraction of blood, use of RNAase-free materials, and transport in a cold chain, which makes difficult the management of samples in developing countries.
Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ cells. According to recent research published in the Journal of Experimental Medicine, "Dendritic cells (DCs) are essential antigen-presenting cells for the induction of T cell immunity against pathogens such as human immunodeficiency virus (HIV)-1. At the same time, HIV-1 replication is strongly enhanced in DC-T cell clusters, potentially undermining this process."
According to a recent report from Germany, "Nanobacteria are suspected to be responsible for a number of diseases, i.e., kidney stones, heart disease, ovarian cancer, peripheral neuropathy, and reduced bone mineral density. Being protected by a mineral shell consisting of apatite, the nanovesicles can enter eukaryotic cells."
According to a study from France, "There is an urgent need for low-cost human immunodeficiency virus type 1 (HIV-1) viral load (VL) monitoring technologies in resource-limited settings.
"Current immunological opinion holds that myeloid dendritic cell (mDC) precursors migrate from the blood to the tissues, where they differentiate into immature dermal-and Langerhans-type dendritic cells (DC).
According to a study from the United States, "Clinical studies indicate that Neisseria gonorrhoeae (gonococci (GC)) has the capacity to enhance HIV type 1 (HIV-1) infection. We studied whether GC enhances HIV infection of activated dendritic cells (DCs)."
Postexposure practice is inadequate in medical students with needlestick injury. According to a study from Canada, "Medical students are at a particularly high risk for needlestick injury and its consequences because of their relative inexperience and lack of disability insurance."
Risk of acquired rifampin resistance in HIV/tuberculosis-coinfected patients depends on the rifampin dosing schedule. According to recent research from the United States, "The relationship between rifamycin use and either relapse or treatment failure with acquired rifampin resistance (ARR) among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) is not well understood.
Peptides derived from HIV-1 reverse transcriptase are inhibitors of the viral integrase. According to recent research from Israel, "Recent studies have shown that the integrase (IN) of HIV-1 is inhibited in vitro by HIV-1 reverse transcriptase (RT).
HIV-associated dementia may be related to changes in molecular factors involved in the infection process. "We previously showed that the envelope glycoprotein from an in vitro microglia-adapted human immunodeficiency virus type 1 isolate (HIV-1(Bori)-15) is able to use lower levels of CD4 for infection and demonstrates greater exposure of the CD4-induced epitope recognized by the 17b monoclonal antibody than the envelope of its parental, peripheral isolate (HIV-1(Bori)).
Resting naive CD4+ cells are massively infected and eliminated by X4-tropic simian HIV in macaques. "Unlike HIV-1 and simian immunodeficiency virus (SIV), which induce a slow, unrelenting loss of immune function spanning several years, highly pathogenic simian-human immunodeficiency viruses (SHIVs) induce a rapid, complete, and irreversible depletion of CD4+ T lymphocytes in rhesus monkeys within weeks of infection, leading to death from immunodeficiency.
The risk of triple-class antiretroviral drug failure is declining in Denmark. "To analyze the incidence, prevalence, and predictors for development of triple-class antiretroviral drug failure (TCF) in individuals infected with HIV," a population based "observational cohort study from January 1, 1995 to December 31, 2003" focused "on all 2722 recipients of highly active antiretroviral therapy (HAART) in Denmark."
Artificial zinc finger fusions repress HIV-1 transcription and replication. According to a study from South Korea, "Tat activates transcription by interacting with Sp1, NF-kappa B, positive transcription elongation factor b, and trans-activator-responsive element (TAR). Tat and Sp1 play major roles in transcription by protein-protein interactions at human immunodeficiency virus, type 1 (HIV-1) long terminal repeat."
HIV Nef protein promotes the survival of infected cells. According to a recent review from India, "The accessory Nef protein is expressed by all primate lentiviruses - HIV-1, HIV-2 and simian immune deficiency virus (SIV).
The CD4:CD8 ratio or CD4 percentage helps determine the risk of disease progression in HIV-infected patients on HAART. In a recently published article, scientists in Australia conducted a study "to determine the factors associated with clinical progression (AIDS events and death) in antiretroviral-naive patients who have begun highly active antiretroviral therapy (HAART).
Stavudine adherence improves with a switch to once-daily dosing. "Adherence to antiretroviral therapy is critical to treatment outcomes. Adherence studies in other therapeutic areas of medicine suggest that once-daily regimens support improved adherence when compared to twice-daily therapy.
A branded advertising campaign increased condom use in Tanzania. According to a study from the United States, "This paper uses retrospective event-history data covering a 4-year period to examine the timing of exposure to HIV/AIDS education and social marketing condom promotion campaigns, relative to the timing of changes in sexual risk behavior in Tanzania."
A satellite pharmacy at an HIV clinic improves physician-pharmacist interaction. "The aim of the study was to investigate how health-care personnel at a HIV clinic perceived conventional pharmacies in Sweden and whether the decentralization of pharmaceutical services to the HIV clinic had led to an improved collaboration between other health-care professionals and pharmacists.
Cocaine upregulates DC-SIGN expression on dendritic cells in HIV infection. "We report that cocaine may act as cofactor in HIV pathogenesis by increasing dendritic cell-specific C type ICAM-3-grabbing nonintegrin (DC-SIGN) expression on dendritic cells (DC).
1) HIV-1 envelope V2 region influence HIV entry and spread in macrophages. 2) Rodent cells support key functions of HIV-1 Nef. 3) Separate HIV Nef domains are required to affect MHC-1 and CD4 cells.
HIV-1-specific CD4 cell responses plus IgG2 antibody predicts long-term nonprogression. "Strong T cell and antibody responses to human immunodeficiency virus (HIV), low virus production, and some genetic traits have been individually associated with nonprogression of HIV infection, but the best correlate with protection against disease progression remains unknown.
Docetaxel is rapidly effective in anthracycline-pretreated AIDS-related Kaposi's sarcoma patients. "Kaposi's sarcoma (KS) is a potentially life-threatening multifocal neoplasm. Despite the significant decline in the incidence of acquired immune deficiency syndrome (AIDS)-related KS with the use of highly active antiretroviral therapy (HAART), some patients, even those with a good immune restoration, still have aggressive disease," researchers in France report.
HIV-infected females with intermediate baseline viral loads have a lower risk of disease progression than men. Investigators from Italy assessed "gender differences in the long-term clinical, virological and immunological outcomes during highly active antiretroviral therapy (HAART)."
HIV-specific IgA can neutralize HIV replication inside cells. According to recent research from the United States, "HIV is transmitted sexually through mucosal surfaces where IgA Abs are the first line of immune defense. In this study, we used paired IgA and IgG mAbs against HIV gp160 to study intraepithelial cell neutralization and inhibition of HIV replication."
Maternal HIV infection may reduce levels of measles antibodies in newborns. "Young infants are protected from measles infection by maternal measles antibodies. The level of these antibodies at birth depends on the level of antibodies in the mother and the extent of placental transfer," researchers in England report.
CD8+ cells are a major determinant of HTLV-1 proviral load. "The CD8+ lymphocyte response is a main component of host immunity, yet it is difficult to quantify its contribution to the control of persistent viruses.
Emergency departments are effectively used as public health programs for HIV-risk populations. "Accessing at-risk and underserved populations for intervention remains a major obstacle for public health programs. Emergency departments (EDs) care for patients not otherwise interacting with the health care system, and represent a venue for such programs," scientists in the United States report.
Nonreplicating HIV-1 virions contribute to T cell depletion by activating CD4+ and CD8+ T cells. "Apoptosis of uninfected bystander T cells contributes to T-cell depletion during human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 envelope/receptor interactions and immune activation have been implicated as contributors to bystander apoptosis.
According to published research from the United States, "A dried blood spot (DBS) is a well-accepted means for the collection, transport, and storage of blood samples for various epidemiologic, serologic, and molecular assays for human immunodeficiency virus (HIV) studies. It is particularly important for mother-to-infant-transmission studies of affected individuals living in remote areas."
"Bordetella pertussis toxin B-oligomer (PTX-B) has been shown to inhibit HIV infection and replication in vitro. The potential anti-viral effect of PTX-B was tested here in an in vivo surrogate model of HIV infection, i.e.," scientists in Italy report.
According to a published report from China, "While 70% of HIV positive individuals live in sub-Saharan Africa, it is widely believed that the future of the epidemic depends on the magnitude of HIV spread in India and China, the world's most populous countries.
"The use of natural health products (NHPs) within the HIV community is high. Several NHPs have demonstrated interactions with HIV medications that could contribute to drug failure.
According to recent research published in the Journal of Virological Methods, "A highly sensitive nested PCR was carried out in order to detect 2 LTR circles as a marker of recent and ongoing vital replication in HIV-1 infected patients with HIV plasma RNA undetectable.
According to published research from France, the antimicrobial peptide Dermaseptin inhibits human immunodeficiency virus-1 (HIV-1) infectivity in vitro.
"Griffithsin (GRFT), a novel anti-HIV protein, was isolated from an aqueous extract of the red alga Griffithsia sp. The 121-amino acid sequence of GRFT has been determined, and biologically active GRFT was subsequently produced by expression of a corresponding DNA sequence in Escherichia coli.
An EcoHIV murine model is used to study systemic HIV-1 infection. According to a recently published report from the United States, "We created a model of HIV-1 infection of conventional mice for investigation of viral replication, control, and pathogenesis.
HIV-1 CCR5 activation/expression on T cells correlates with disease progression. "The objective of this paper was to investigate the activation and coreceptor CCR5, CXCR4 expression of T lymphocytes in HIV/AIDS patients of China, and to study their association with disease progression.
An antiviral high throughput approach was used to screen HIV-1 inhibitors. "Antiviral high throughput screens remain a viable option for identifying novel target inhibitors. However, few antiviral screens have been reduced to practice on an industrial scale.
According to a recent report from Jamaica, "The acquired immune deficiency syndrome (AIDS) epidemic is spreading fast in Africa in spite of the various efforts and resources put in place to prevent it.
Molecular modeling revealed a new HIV-1 integrase binding site for nucleotide inhibitors. "HIV-1 integrase (IN) is an important target for designing new antiviral therapies. Screening of potential inhibitors using recombinant IN-based assays has revealed a number of promising leads including nucleotide analogs such as pyridoxal 5'-phosphate (PLP). Certain PLP derivatives were shown to also exhibit antiviral activities in cell-based assays," researchers in the United States report.
There is a high degree of HIV-2-specific T cell activity in HIV-2-exposed uninfected and infected persons. According to a recently published study from Sweden, "Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses were determined in cultures of peripheral blood mononuclear cells from HIV-2-exposed uninfected individuals, HIV-2-infected individuals and HIV-negative controls in Guinea-Bissau."
HIV/tuberculosis-infected persons have difficulty accessing antiretroviral therapy outside the Malawi hospital setting. "The World Health Organization (WHO) has set a target of treating 3 million people with antiretroviral treatment (ART) by 2005. In sub-Saharan Africa, HIV-positive tuberculosis (TB) patients could significantly contribute to this target.
HIV non-B subtypes are circulating in Italy. According to a recently published report from Italy, "A total of 347 pol gene sequences from 88 Tuscan and 259 Apulian subjects (including 52 non-Italians and 9 children) were analyzed phylogenetically.
Neutralizing/nonneutralizing IgG captures HIV-1 via antibodies against gp41. According to a recent report published in the journal Virology, "We analyzed the factors influencing the binding of polyclonal inummoglobutin (Ig)G from HIV-infected patients to primary isolates (PI) in capture assays and a potential correlation between this binding and neutralization.
B30.2(SPRY) domain is the major determinant of anti-HIV-1 potency. According to recently published research from the United States, "Retroviruses encounter dominant postentry restrictions in cells of particular species.
Sulfonated naphthyl porphyrins active against HIV-1. "Sulfonated 5,10,15,20-tetra(1-naphthyl)porphyrin (T1NapS) and 5,10,15,20-tetra(2-naphthyl)porphyrin (T2NapS) and their copper and iron chelates show activity against the human immunodeficiency virus (HIV-1).
Lipid-lowering drugs may cause pharmacokinetic interactions with antiretrovirals. According to a recent report from the United States, "Dyslipidemia and coronary heart disease (CHD) are of increasing concern in persons with human immunodeficiency virus (HIV) infection who are living longer because of the benefits of highly active antiretroviral therapy (HAART). All classes of drugs used in HAART have been associated with atherogenic changes in lipid profiles."
Pyridine N-oxide derivatives protects against HIV-induced CD4 cell destruction. According to a study from Belgium, "Pyridine N-oxide derivatives represent a new class of anti-HIV compounds, for which some members exclusively act through inhibition of HIV-1 reverse transcriptase and thus characteristically behave as non-nucleoside reverse transcriptase inhibitors."
Endocytosis contributes to productive HIV entry. "Productive entry of human immunodeficiency virus (HIV) is believed to occur by direct fusion at the plasma membrane. Endocytic uptake of HIV particles has been observed in several studies but is considered to be nonproductive, leading to virus degradation in the lysosome.
"Human immunodeficiency virus-1 (HIV-1) Vpr encodes a 14 kDa protein that has been implicated in viral pathogenesis through in vitro modulation of several host cell functions. Vpr modulates cellular proliferation, cell differentiation, apoptosis and host cell transcription in a manner that involves the glucocorticoid pathway.
"A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIIV-1) protease, in 20 HIV-infected children 4 to 12 years of age.
Amphotericin-B reactivates latent HIV-1 infection. According to recently published research from the United States, "To date, attempts to eliminate HIV-1 infection from its latent reservoirs, a prerequisite for the development of a curative treatment strategy for HIV-1 infection, have been unsuccessful.
Supervised medication delivery or simplified dosing regimens may be needed to ensure that HIV-infected patients with a history of alcohol problems stick to their medication regimens, according to a new study by researchers at Boston University Medical Center.
Lopinavir plasma concentrations are higher when combined with valproic acid. According to recent research from the United States, "Valproic acid (VPA) has the potential to benefit patients suffering from human immunodeficiency virus (HIV)-associated cognitive impairment. The purpose of this study was to determine if VPA affects the plasma concentration of efavirenz (EFV) or lopinavir.
Saquinavir and miconazole are synergistic against Candida albicans/C. neoformans. "Candidiasis and cryptococcosis are the most common fungal diseases among patients suffering from HIV infection. In the present work we assess whether the combined therapies, proteinase inhibitors and antimycotic drugs, could modify the therapeutic effect of antimycotics.
A distinct HIV-1 subtype, A3, is circulating in West Africa. "Phylogenetic analyses demonstrate significant diversity in worldwide circulating strains of human immunodeficiency virus type 1 (HIV-1). Detailed studies have revealed a complex pattern of intersubtype recombinations, as well as evidence of sub-subtypes circulating in various populations.
Novel targets are identified for HIV-1 treatment. "Human immunodeficiency virus type 1 (HIV-1) impacts multiple lineages of hematopoietic cells, including lymphocytes and macrophages, either by direct infection or indirectly by perturbations of cell networks, leading to generalized immune deficiency.
Atomic force microscopy images have been obtained of HIV and MuLV. "Retroviruses are membrane-enveloped, RNA-containing viruses that produce a wide range of threatening diseases in higher animals. Among these are human immunodeficiency virus (HIV), which produces acquired immune deficiency syndrome (AIDS) in humans, and murine leukemia virus (MuLV), which produces leukemias in rodents.
HIV integrase inhibitors are identified via a phage display technique. "Human immunodeficiency virus type 1 integrase catalyzes the integration of proviral DNA into the infected cell genome, so it is an important potential target for antiviral drug design.
A stavudine formulation from India is bioequivalent to the reference drug from Bristol-Myers Squib. According to scientists writing in the journal Pharmacological Research, "Stavudine (d4T), a thymidine nucleoside analogue has been effectively used for treatment of patients infected with HIV.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
